Format

Send to

Choose Destination
Mol Med Today. 1999 Jan;5(1):18-24.

Expanded-capacity adenoviral vectors--the helper-dependent vectors.

Author information

1
Dept of Human Genetics, Merck & Co., Inc., West Point, PA 19486, USA. morsy@merck.com

Abstract

Significant advances have recently been made in the development of vectors and gene-delivery systems for gene therapy. Experiments performed over the past decade have revealed how vectors will have to be modified to make them a clinically viable treatment option. In the case of adenovirus (Ad) vectors, which have been particularly useful as gene delivery vehicles, the main drawback associated with their use is vector-mediated immunogenicity. Recent modifications of the Ad backbone have led to the development of helper-dependent (HD) Ad vectors, which are completely devoid of all viral protein-coding sequences. These modifications have significantly reduced the immunogenicity of Ad vectors and have enhanced their safety. It is expected that HD vectors will become important tools for future clinical gene therapy.

PMID:
10088128
DOI:
10.1016/s1357-4310(98)01376-8
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center